Andino v. Novo Nordisk A/S et al
| Alyssa Andino |
| NOVO NORDISK A/S, NOVO NORDISK NORTH AMERICA OPERATIONS A/S, NOVO NORDISK US HOLDINGS INC., NOVO NORDISK US COMMERCIAL HOLDINGS INC., NOVO NORDISK INC., NOVO NORDISK RESEARCH CENTER SEATTLE INC., NOVO NORDISK PHARMACEUTICAL INDUSTRIES L.P. and ELI LILLY AND COMPANY |
| 2:2024cv00531 |
| February 5, 2024 |
| US District Court for the Eastern District of Pennsylvania |
| GENE EK PRATTER |
| P.I.: Health Care/Pharmaceutical Personal Injury Product Liability |
| 28 U.S.C. § 1332 Diversity-Product Liability |
| Plaintiff |
Docket Report
RSS Track this Docket
This docket was last retrieved on February 22, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 12 WAIVER OF SERVICE Returned Executed by Alyssa Andino. ELI LILLY AND COMPANY waiver sent on 2/22/2024, answer due 4/22/2024. (ANELLO, VIRGINIA) |
| MDL-3094 (Judge Pratter) Member Case. EDNY 2:23cv8868. Case number in EDPA: 2:24cv531. (nd) |
| Filing 11 Case transferred in from District of New York Eastern; Case Number 2:23-cv-08868. Original file certified copy of transfer order and docket sheet received. |
| Filing 10 Certified JPMDL Conditional Transfer Order IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION MDL No. 3094. IT IS THEREFORE ORDERED that the actions listed on Schedule A and pending outside the Eastern District of Pennsylvania are transferred to the Eastern District of Pennsylvania and, with the consent of that court, assigned to the Honorable Gene E. K. Pratter for coordinated or consolidated pretrial proceedings. (LF) [Transferred from New York Eastern on 2/5/2024.] |
| Case transferred to District of Eastern District of Pennsylvania. Original file, certified copy of transfer order, and docket sheet sent. ALL FILINGS ARE TO BE MADE IN THE TRANSFER COURT, DO NOT DOCKET TO THIS CASE. (LF) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 9 JPMDL Conditional Transfer Order IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION MDL No. 3094. IT IS THEREFORE ORDERED that the actions listed on Schedule A and pending outside the Eastern District of Pennsylvania are transferred to the Eastern District of Pennsylvania and, with the consent of that court, assigned to the Honorable Gene E. K. Pratter for coordinated or consolidated pretrial proceedings. (GO) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 8 NOTICE of Electronic Filings Entered In RE: GLUCAGON-LIKE PEPTIDE-I RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION, MDL No. 3094. (GO) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 6 NOTICE from Counsel Morgan & Morgan to EDNY dated 12/4/2023 Re: Plaintiffs' Motion for Transfer of Actions to the United States District Court for the Western District of Louisiana, along with five (5) attachments and one (1) CD containing 36 exhibits, filed on December 1, 2023, in the above-referenced matter. (GO) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 5 Summons Issued as to Eli Lilly and Company, Novo Nordisk A/S, Novo Nordisk North America Operations A/S, Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Research Center Seattle, Inc., Novo Nordisk US Commercial Holdings, Inc., Novo Nordisk US Holdings, Inc., Novo Nordisk, Inc. (AMF) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 4 Proposed Summons. by Alyssa Andino (Anello, Virginia) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 7 NOTICE received from United States Judicial Panel on Multidistrict Litigation IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Litigation. (Attachments: #1 Attachment 1) (CT) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 3 Clerks Notice Re: Consent. A magistrate judge has been assigned as the presiding judge in this case as part of a Pilot Program, governed by EDNY Administrative Order 2023-23. In accordance with Rule 73 of the Federal Rules of Civil Procedure, Local Rule 73.1, the parties are notified that if all parties consent, the assigned Magistrate Judge is available to conduct all proceedings in this action including a (jury or nonjury) trial and to order the entry of a final judgment. Attached to this Notice is a blank copy of the consent form that should be filled out, signed and filed electronically only if all parties wish to consent. The form is also available here: #https://www.nyed.uscourts.gov/edny-direct-assignment-pilot-program. Any party may withhold its consent without adverse substantive consequences. Do NOT return or file the consent unless all parties have signed the consent. Unless all parties consent to the Magistrate Judge jurisdiction by the deadline set forth in the Administrative Order 2023-23, a District Judge will be assigned to the case. The parties are directed to review the terms of Administrative Order 2023-23 and other materials related to the Pilot Program on the Courts website: #https://www.nyed.uscourts.gov/edny-direct-assignment-pilot-program. (LJ) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 2 This attorney case opening filing has been checked for quality control. See the attachment for corrections that were made. (LJ) [Transferred from New York Eastern on 2/5/2024.] |
| Case Assigned to Magistrate Judge Lee G. Dunst. Please download and review the Individual Practices of the assigned Judges, located on our #website. Attorneys are responsible for providing courtesy copies to judges where their Individual Practices require such. (LJ) [Transferred from New York Eastern on 2/5/2024.] |
| Your proposed summons was not issued for the following reason: The full case caption must appear on the summons and/or the attached rider. Please correct and resubmit using the event Proposed Summons/Civil Cover Sheet. (LJ) [Transferred from New York Eastern on 2/5/2024.] |
| Filing 1 COMPLAINT against Eli Lilly and Company, Novo Nordisk A/S, Novo Nordisk North America Operations A/S, Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Research Center Seattle, Inc., Novo Nordisk US Commercial Holdings, Inc., Novo Nordisk US Holdings, Inc., Novo Nordisk, Inc. filing fee $ 405, receipt number ANYEDC-17338095 Was the Disclosure Statement on Civil Cover Sheet completed -NO,, filed by Alyssa Andino. (Attachments: #1 Civil Cover Sheet, #2 Proposed Summons) (Anello, Virginia) [Transferred from New York Eastern on 2/5/2024.] |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Pennsylvania Eastern District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
